Prevalence and Trends in Obesity Among Hospitalized Children

Kathryn E Kyler1, Jessica L Bettenhausen2, Matthew Hall2,3

  • 1Division of Hospital Medicine and kekyler@cmh.edu.

Hospital Pediatrics
|October 25, 2019
PubMed

Insights

Childhood obesity is rising, with 17% of hospitalized children having obesity. This prevalence increased slightly from 2009-2016, particularly in orthopedic and infectious disease cases.

Area of Science:

  • Pediatric Health
  • Public Health Research
  • Clinical Epidemiology

Background:

  • Rising childhood obesity rates necessitate understanding the inpatient pediatric population.
  • Characterization of hospitalized children with obesity is currently lacking.
  • Identifying trends and associated factors is crucial for targeted interventions.

Purpose of the Study:

  • To analyze trends in the annual prevalence of pediatric obesity in hospitalizations.
  • To identify demographic and clinical factors linked to higher obesity prevalence in hospitalized children.

Main Methods:

  • Retrospective cohort analysis of children (2-19 years) hospitalized between 2009-2016.
  • Obesity defined using CDC age- and sex-specific BMI percentile guidelines.
  • Statistical analysis included chi-squared tests and Cochran-Armitage test for trends.

Main Results:

  • Overall obesity prevalence in hospitalized children was 17.0%, increasing from 16.5% to 17.3% (2009-2016).
  • Highest obesity prevalence observed in orthopedics (22.1%), infectious disease (20.6%), and neuroscience (18.7%) service lines.
  • Specific diagnosis groups with high obesity prevalence included cellulitis (22.5%) and tonsil/adenoid procedures (22.0%).

Conclusions:

  • Certain pediatric groups, including those with orthopedic, infectious disease, and neurological conditions, show higher obesity prevalence.
  • Future research should focus on these disproportionately affected groups.
  • Investigate health outcomes, patient safety, and satisfaction in hospitalized children with obesity.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
210
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
184
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
144
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
210
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
227